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The recruitment of monocytes from the bloodstream is
crucial in the accumulation of macrophages and den-
dritic cells in type 1 diabetic pancreases. Adhesion via
integrins to endothelium and extracellular matrix pro-
teins, such as fibronectin (FN), and the production of
myeloid-related protein (MRP)-8, -14, and -8/14 by re-
cently transmigrated monocytes are thought to be in-
strumental in such recruitment. We determined the
FN-adhesive capacity and integrin expression of mono-
cytes of type 1 and type 2 diabetic patients and related
them to the subjects’ serum levels of MRP-8, -14 and
-8/14. Monocytes of type 1 diabetic patients displayed
an increased adhesion to fibronectin in comparison with
type 2 patients and healthy control subjects but had a
normal expression of the FN binding integrins CD29,
CD49a, CD49d, and CD49e (although CD11b and CD18
expression was increased). MRP-8/14, which was in-
creased in the sera of type 1 diabetic patients, induced
healthy donor monocytes to adhere to FN and upregu-
late CD11b expression in a dosage-dependent manner.
The observed MRP-induced increased adhesion of mono-
cytes to FN and upregulation of CD11b most likely
contributed to a facilitated accumulation of monocytes
and monocyte-derived cells at the site of inflammation,
in this case the pancreatic islets. Diabetes 53:
1979–1986, 2004
A part from lymphocytes, dendritic cells (DCs)and various types of macrophages accumulatein the type 1 diabetes pancreas (1). In the NODmouse and the BB-DP rat, animal models of the
disease, DCs and macrophages are among the first cells to
accumulate in and around the islets (2–5), suggesting that
these cells play a key role in the development of islet
autoimmunity.
Various abnormalities have been described in the devel-
opment and function of DCs, macrophages, and mono-
cytes (important precursors for DCs and macrophages) in
type 1 diabetes. In the NOD mouse, there is evidence that
before insulitis onset, the development of DCs and mac-
rophages from bone marrow precursors is disturbed (6,7),
resulting in cells with a poor antigen-presenting cell (APC)
function (7,8), but an enhanced inflammatory phenotype
(T. Nikolic and G.B., unpublished observations). DCs have
raised nuclear factor-B (NF-B) activity (9,10), and NOD
macrophages produce higher quantities of proinflamma-
tory compounds such as prostaglandin E2 (11,12) and
interleukin (IL)-12 (13). Also in the BB-DP rat, spleen DCs
are poor APCs (14), with macrophages exhibiting an
elevated production of NO (15). Human studies have
focused mainly on circulating monocytes. As in the animal
models, cells show poor APC function and an enhanced
proinflammatory cytokine production (16,17). There are,
however, few studies on adhesion molecule expression
and chemotactic ability of diabetic monocytes.
The recruitment of monocytes from the blood stream
must play a crucial role in the accumulation of DCs;
macrophages in the pancreas and aberrances in this
process may play an additional role in local abnormalities
of the cells. Recruitment involves the expression of adhe-
sion molecules on the vascular endothelium and activated
monocytes, as well as the adhesion and transmigration of
the monocytes (18,19). In the islets, monocytes will inter-
act with extracellular matrix (ECM) proteins, such as
fibronectin (FN), and will differentiate into macrophages
and dendritic cells.
We first explored the adhesion of circulating monocytes
of type 1 and type 2 diabetic patients to FN in the absence
or presence of N-formyl-methionyl-leucyl-phenylalanine
(fMLP), a cleavage product of bacterial and mitochondrial
proteins that is generally used as a potent stimulatory
agent for neutrophils and monocytes (20). After mono-
cytes adhere to FN, a rearrangement of the cortical
actomyosin cytoskeleton takes place, resulting in stretch-
ing and spreading of the monocytes on the FN-coated
surface (21). We found an increased adhesion to and
stretching on FN-coated surfaces of type 1 diabetes circu-
lating monocytes in both the absence and presence of
fMLP.
The increased adhesion and stretching of the total pool
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of circulating monocytes might be explained by a differ-
ence in the apportioning between different subsets of
circulating monocytes. In humans, the circulating mono-
cyte pool can be divided into CD14CD16 and
CD14CD16 monocytes (22), which display distinct traf-
ficking and adhesion properties (23,24). Monocyte che-
moattractant protein-1 upregulates CD11b expression on
CD14CD16 monocytes, but not on CD14CD16 mono-
cytes, as the latter are low in C-C chemokine receptor 2.
This illustrates the different potential of the subpopula-
tions to express adhesion molecules. It is notable that an
expansion of the CD14CD16 monocyte subset has been
observed in autoimmune rheumatoid arthritis and inflam-
matory diseases, such as HIV infection and sepsis (25–27).
We therefore investigated whether the increased adhesion of
the circulating monocyte pool of type 1 diabetic patients to
FN could be ascribed to a difference in adhesion of the
monocyte populations. We could not, however, detect any
differences in the adhesion to FN of the two populations, nor
could we find a difference in the size of these populations.
Myeloid-related protein (MRP)-8 and -14 are calcium-
binding proteins of the S100 family. These proteins form a
heterodimeric complex in a calcium-dependent manner
and are specifically expressed by recently transmigrated
monocytes and granulocytes (28). MRP-8– and MRP-14–
expressing cells dominate inflammatory reactions. Stimu-
lation of monocytes with granulocyte-macrophage colony-
stimulating factor, IL-1, or lipopolysaccharide induces
the expression and secretion of the MRP-8/14 heterodimer
(29). When monocytes are stimulated with MRP-14 or
-8/14, a rapid increase in their CD11b surface expression is
observed (30). Although the precise function of the MRPs
is still unclear, they are thought to be involved in leuko-
cyte-endothelium interactions and to play an important
role in leukocyte trafficking (30,31).
We therefore also investigated the level of MRPs in the
sera of type 1 and type 2 diabetic patients and explored
whether an association exists between the serum levels of
MRP proteins and the adhesion of circulating monocytes
of type 1 and type 2 diabetic patients to FN. In addition, we
studied the relation of the MRP levels in the serum with
the surface expression of various adhesion molecules
(CD11b, CD18, CD29, CD49a, CD49d, and CD49e) on
monocytes of type 1 and type 2 diabetic patients. We
showed that the enhanced adhesion of the type 1 diabetic
circulating monocyte pool to FN is due to an increased
level of MRP-8/14 and that the increased serum levels of
MRP-8/14 in type 1 diabetic patients correlate with an
increased CD11b expression on circulating monocytes.
RESEARCH DESIGN AND METHODS
Heparinized blood was drawn from type 1 diabetic patients (30 men: average
age 35.0 3.1 years [ SE], HbA1c 8.5 0.5%, duration of diabetes after initial
diagnosis 15.0  2.9 years; and 22 women: age 41.7  2.5 years, HbA1c 8.6 
0.4%, duration of diabetes after initial diagnosis 22.7  3.2 years) and healthy
control subjects matched for age and sex (12 men: age 38.8  3.4 years; 9
women: age 33.8  7.7 years). In addition, blood was drawn from type 2
diabetic patients as disease control subjects (8 men: age 52.9  4.0 years,
HbA1c 7.8  0.3%; and 14 women: age 56.9  3.6 years, HbA1c 8.0  0.4%).
Patients with obvious vascular complications and/or recent surgical interven-
tions were excluded from this study.
Sera were collected and used for the detection of MRP-8, -14, and -8/14.
Monocytes were isolated using an adaptation of the protocol described by
Fluks (32). Briefly, blood was diluted 1.5 times with PBS containing 0.1% BSA
(Biowhittaker, Verviers, Belgium), layered on a Ficoll gradient (1.077 g/ml;
Pharmacia, Uppsala, Sweden), and centrifuged (1000g, 15 min, room temper-
ature). The cells at the interface were collected, washed, layered on a Percoll
gradient (1.063 g/ml; Pharmacia), and centrifuged (400g, 40 min, room
temperature). The monocytes were collected from the interface and washed
to a final purity of 85–95%.
The Medical Ethics Committee of the Erasmus Medical Center (Rotterdam)
approved this study on collected blood monocytes. All subjects gave their
written informed consent.
Adhesion and stretching of patient and control monocytes. Monocytes
were suspended in RPMI 1640 containing 100 units/ml penicillin, 100 g/ml
streptomycin, and 10% heat-inactivated fetal bovine serum (Biowhittaker),
plated on Chambertek glass slides (0.1  105 cells/chamber; Nalge Nunc,
Naperville, IL), and coated with 10 g/ml fibronectin (Sigma, Steinheim,
Germany). After a 15-min incubation at 37°C in the absence or presence of the
stimulatory agent fMLP, the cells were washed with PBS and fixed with 4%
paraformaldehyde (Sigma) supplemented with 3% glucose. The cells were
permeabilized using 0.5% Triton X-100 (Sigma) and stained with 0.1 g/ml
phalloidin-fluorescein isothiocyanate (Sigma) for 30–45 min. After cells were
washed and mounted on slides, adhesion was determined as the number of
cells in 10 high-power fields using a fluorescence microscope at 200
magnification. Stretching was recorded as the percentage of cells with a
stretched morphology (Fig. 1C). Two individuals counted at least 200 cells
independently.
Integrin expression and cell sorting. The expression of CD11b, CD18,
CD29, CD49a, CD49d, and CD49e on CD14 monocytes in heparinized blood
was determined using flow cytometry on a FACSscan (Becton Dickinson, San
Jose, CA) and CellQuest software (BD Pharmingen). Whole blood samples
were stained with the appropriate antibodies (BD Pharmingen, Alphen aan
den Rijn, Netherlands), and then washed with PBS containing 0.1% BSA; the
erythrocytes were lysed using BD lysing buffer (BD Pharmingen) for 10 min at
room temperature. Samples were subsequently washed and analyzed.
FIG. 1. Time-dependent adhesion of monocytes to FN in the absence
(A) and presence (B) of fMLP. At 15 min, data represent means  SE
of 10 type 1 patients (DM1), 6 type 2 diabetic patients (DM2), and 8
healthy control subjects; at the other time points, n  3 (Student’s t
test). For 15-min data, one-way ANOVA with Bonferroni correction was
used. *P < 0.05 vs. controls, #P < 0.05 vs. type 2 patients. C: Examples
of spreading and stretching (, nonstretched; , stretched or spread).
The percentage of spread and stretched cells in the different test
groups at 15 min is given in D (means  SE, same n as in A and B,
one-way ANOVA with Bonferroni correction).
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For cell sorting, monocytes were labeled with CD14 and CD16 antibodies
(BD Pharmingen). After sorting (FACS Vantage; Becton Dickinson, Amster-
dam, Netherlands), the purity of the cell suspensions was 95%.
Myeloid-related protein detection. Levels of MRP-8, -14, and -8/14 were
measured in serum by a commercially available enzyme-linked immunosor-
bent assay (ELISA; Bachem, Heidelberg, Germany) according to the manufac-
turer’s protocol.
Adhesion assay in the presence of subject or control serum. Monocytes
were obtained from a buffy coat of a healthy control donor (Sanquin Blood
Bank, Rotterdam, Netherlands) using Ficoll and Percoll gradients. Donor
monocytes were exposed for 4 h at 37°C to dilutions of sera of either type 1
diabetic patients or healthy control subjects. After being exposed, cells were
washed and allowed to adhere to FN-coated 96-well plates for 60 min at 37°C
(note that this assay differs from the above-described adhesion assay in which
adhesion was determined by individual cell counting). Cells were fixed using
20% formaldehyde (Sigma) and stained with 1% methylene blue (BDH Chem-
icals, Poole, England). Staining intensity was determined by measuring
absorption at a wavelength of 650 nm using an ELISA reader (Thermo Lab
Systems, Amersfoort, Netherlands) and a rate of cell adhesion. The assay was
validated by comparing the staining intensities to direct cell counts (data not
shown). In some cases, serum was depleted of MRP-8/14 by immunoprecipi-
tation with an antibody against MRP-8/14 (Bachem); an unrelated monoclonal
antibody with the same isotype was used as the control (Santa Cruz,
Heerhugowaard, Netherlands). Sera were incubated with the antibodies for 60
min at 4°C and then protein A sepharose (Pharmacia) for 60 min at 4°C, and
then centrifuged briefly at 12,000g. The supernatant was used to expose the
cells, as described above.
Statistical analyses. Data were analyzed using one-way ANOVA with
Bonferroni correction, unpaired Student’s t test, or Mann-Whitney U test.
Correlation was examined using Spearman’s rho test. All data were tested for
two-tailed significance. P 	 0.05 was considered to be statistically significant.
RESULTS
Adhesion, stretching, and spreading of monocytes.
Monocytes of type 1 and type 2 diabetic patients and
healthy control subjects were isolated from the blood and
allowed to adhere to an FN-coated surface in the absence
or presence of fMLP. Adhesion was determined at several
time points (5–120 min); monocytes reached maximal
adhesion at 60–120 min. As shown in Fig. 1A and B,
monocytes of type 1 diabetic patients displayed an in-
creased adhesion to FN in comparison with monocytes of
healthy control subjects at all time points studied and in
the absence and presence of fMLP (although stimulation
of the monocytes with fMLP resulted in an increased
adhesion to FN). Because the monocytes showed an
increased adhesion at all time points studied, we con-
cluded that the monocytes of type 1 diabetic patients
display a higher, rather than a faster, adhesive capacity.
Monocytes of type 2 diabetic patients were studied as
disease controls at time point 15 min only; they had
adhesion properties equal to those of healthy control
monocytes (Fig. 1A and B).
After monocytes adhere to FN, a rearrangement of the
cortical actomyosin cytoskeleton takes place, leading to a
stretching of the cells. Figure 1C shows representative
stretched monocytes to illustrate the changes in shape
encountered. After 15 min of incubation, more type 1
diabetic monocytes displayed a stretched morphology
than type 2 diabetic and healthy control monocytes, in
both the absence and the presence of fMLP (Fig. 1D).
CD14CD16 and CD14CD16monocytes and adhe-
sion to FN. To study whether a putative shift in the
apportioning between the CD14CD16 and CD14CD16
monocyte populations would be responsible for the above-
described differences in FN adhesion of the total mono-
cyte pool, the two monocyte populations were sorted (Fig.
2A) and their adhesion to an FN-coated surface studied.
Differences could not be detected in the adhesion to FN
between the two populations (Fig. 2B). We also deter-
mined the percentages of both populations in the periph-
eral blood of type 1 and type 2 diabetic patients and
healthy control subjects. Differences in the percentages of
the CD14CD16 monocyte populations in relation to the
total monocyte population also could not be detected (Fig.
2C).
Serum levels of MRP-8, -8/14, and -14. To study the role
of MRP-8/14 and -14 in the increased adhesion of mono-
cytes of type 1 diabetic patients to FN, we determined the
FIG. 2. CD14CD16 and CD14CD16 monocyte subpopulations were
sorted and purities >95% were reached. A: Representative flow cyto-
metric analyses of starting and sorted populations. B: Adhesion to FN
of both subsets was determined; differences were not observed
(means SD, n 3). C: Differences were also not observed among type
1 diabetic patients, type 2 diabetic patients, and healthy control
subjects regarding the percentage of the CD14CD16 monocyte sub-
population in the peripheral blood.
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serum levels of MRP-8, -14, and -8/14. As shown in Fig.
3A–C, the serum levels of MRP-14 and -8/14 were signifi-
cantly higher in type 1 diabetic patients compared with the
levels found in healthy control subjects (MRP-8/14 was the
most significant). MRP-8 levels were normal in type 1
diabetic patients. A close and positive correlation was
found between the levels of MRP-14 and -8/14 (r 
 0.64,
P 	 0.01) (Fig. 3D). Neither a correlation between the
serum levels of both MRPs and HbA1c, nor a correlation
between serum levels of MRPs and patients’ age or dura-
tion of type 1 diabetes could be found (data not shown). In
type 2 diabetic patients, only the level of MRP-8/14 was
determined and was found to be normal (Fig. 3C).
Serum MRP-8/14 levels in relation to monocyte adhe-
sion to FN. To investigate whether the increase in MRP-
8/14 in the serum of type 1 diabetic patients could play a
direct role in the adhesion of monocytes to FN, monocytes
of a healthy control donor were exposed to sera of type 1
diabetic patients or that of healthy control subjects. Figure
4 shows that a higher induction of adhesion to FN was
observed using the sera of type 1 diabetic patients in
comparison with sera of healthy control subjects. This
higher induction of adhesion declined with the dilution of
the serum (Fig. 4A).
To demonstrate a specific role for MRP-8/14 in the
induction of adhesion, sera of type 1 diabetic patients and
control subjects were depleted of MRP-8/14 using a spe-
cific monoclonal antibody. Depletion of the sera was
confirmed using immunoblotting (data not shown). After
exposing the monocytes of a healthy control donor to the
depleted sera, it was found that the adhesion-inducing
capacity of the sera declined. With an irrelevant isotype
control antibody, such an effect was not observed (Fig.
4B).
Serum MRP-8/14 levels and integrin expression on
monocytes. To investigate if the high serum MRP-8/14
levels of type 1 diabetic patients could influence the
expression of integrins, monocytes of healthy donors were
exposed to sera that were depleted of MRP-8/14 or de-
pleted using an irrelevant isotype control antibody. Figure
5A shows that the presence of MRP-8/14 in sera specifi-
cally upregulated the CD11b expression on healthy donor
monocytes. The expression of CD18 was not influenced
(Fig. 5B).
In addition, ex vivo monocytes of type 1 diabetic pa-
tients were studied to investigate whether an upregulation
of CD11b could indeed be detected. Figure 6A and Table 1
show that monocytes of type 1 diabetic patients displayed
a higher expression level of CD11b. Furthermore, a posi-
tive and significant correlation was found between the
serum levels of MRP-8/14 (r 
 0.448, P 	 0.05) (Fig. 5C)
and the CD11b expression on the monocytes. Such a
positive correlation was also present between the MRP-14
level and the CD11b expression (r 
 0.622, P 	 0.01) (Fig.
5D). However, it must be noted that the expression of
CD18 was also (albeit just significantly) raised on ex vivo
monocytes of type 1 diabetic patients as compared with
those of healthy control subjects (Fig. 6B and Table 1).
Moreover, monocytes of type 2 diabetic patients showed a
higher expression level of the CD11b and CD18 integrins
FIG. 3. Serum levels of MRP-8 of 13 control subjects and 13 type 1 patients (A; Student’s t test), MRP-14 of 15 control subjects and 23 type 1
patients (B; Student’s t test), and MRP-8/14 in 18 control subjects, 23 type 1 patients, and 15 type 2 patients (C; one-way ANOVA). nd, not
determined. A positive correlation (Spearman’s rho) was observed between MRP-14 and MRP-8/14 in the serum (D).
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(CD11b: 569  278 vs. 152  78; CD18: 154  59 vs. 76 
31).
With regard to the expression levels of the CD49d,
CD49e, and CD29 integrins (combined forming the FN-
binding adhesion molecules very late antigen [VLA]-4 and
VLA-5), a statistically significant difference between mono-
cytes of type 1 diabetic patients (Fig. 6C–F and Table 1),
type 2 diabetic patients (data not shown), and healthy
control monocytes could not be found.
DISCUSSION
In inflammatory conditions, circulating monocytes change
from a quiescent, nonadhesive state into an adhesive state
characterized by an increased expression of adhesion
molecules and an increase in functional adhesion (18,19).
This activation is associated with a higher secretion of
MRP-8, -14, and -8/14, which contributes to a further
adhesion of the monocytes to the endothelium and a
transmigration into the tissue (30). Contact of transmi-
grated monocytes with the ECM induces a further expres-
sion of MRP-8/14 (33). MRP-8/14 is bound by the vascular
endothelium (28,34), and secretion of MRP-8/14 by mono-
cytes is inhibited by resting endothelial cells (35).
In this study we demonstrated that increased levels of
MRP-8/14 and -14 are present in the sera of type 1 diabetic
patients and are specific for this subtype of diabetes (type
2 diabetic patients had normal levels). An effect of the
hyperglycemic state can be ruled out, as HbA1c levels did
not influence serum MRP-8/14. High serum levels of MRP-
8/14 and -14 are also present in rheumatoid arthritis, in
which the serum level of MRP-8/14 correlates with the
presence of MRP-8/14 in the synovial fluid and with
disease activity (35). Our data thus indicate that MRP-8/14
levels in the peripheral blood of type 1 diabetic patients
may be used as a marker for the activity of the islet
inflammatory response.
Proinflammatory-activated monocytes in the circulation
attach to the endothelium via an interaction between
adhesion molecules like Mac-1 (the heterodimer of CD11b
and CD18) and leukocyte function antigen-1 (LFA-1)
(CD11a and CD18) and the endothelial adhesion molecules
intracellular adhesion molecule (ICAM)-1 and vascular cell
adhesion molecule (VCAM)-1 (36). This interaction is the
first in a sequence of events resulting in the transmigration
of monocytes into the tissue (37). Blocking LFA-1 and
Mac-1 on leukocytes and ICAM-1 on endothelial cells in
NOD mice prevents the onset of diabetes (38–41), indicat-
ing the important role of these adhesion molecules in the
development of diabetes. When monocytes have transmi-
grated through the endothelium, they encounter the ECM,
of which FN is a major component. The monocytes attach
to the ECM via integrins and a complex conjunctional
action between their integrins and components of the
ECM enables them to adhere, change shape, migrate, and
differentiate into macrophages and DCs (42).
We have shown that circulating monocytes of type 1
diabetic patients display increased CD11b and CD18 sur-
face expression, adhesion to FN-coated surfaces, and
stretching on such surfaces. The latter observation sug-
gests increased activity of the actomyosin cytoskeleton
under circumstances of FN adhesion. Previously we re-
ported an aberrant cytoskeletal function of FN-adherent
monocytes of autoimmune thyroiditis patients when the
cells are chemoattracted (43). Hence there is increasing
evidence that integrin expression and function are abnor-
mally regulated in “autoimmune” monocytes. In this study,
the FN adhesion and spreading of the type 1 diabetic
monocytes did not appear to be due to a difference in the
size of the two important subsets in the circulating mono-
cyte pool (i.e., the CD14CD16 and CD14CD16 mono-
cyte subsets). Our data showed that these aberrances
were most likely due to the raised serum MRP-8/14 levels,
because serum of type 1 diabetic patients was able to
induce an increased adhesion of healthy donor monocytes
to FN-coated surfaces and because this activity could be
blocked by specific antibodies to MRP-8/14. Although in
our experiments only MRP-8/14 was depleted from the
serum, MRP-14 might also contribute to the increased
adhesion, as exposure of monocytes to MRP-14 has been
shown to increase the expression of adhesion molecules
(i.e., CD11b) (30) and stimulation of neutrophils with
MRP-14 has been shown to increase both their adhesion to
fibrinogen and their CD11b expression (44).
The increased adhesion of monocytes of type 1 diabetic
patients to FN could be explained by a change in the
affinity of the FN-specific VLA-4 and -5 integrins, given that
we did not observe an increase in the molecular expres-
sion levels of these integrins. Such an increase in affinity
has been shown for VLA-4, of which a pool of low-affinity
FIG. 4. A: Adhesion of healthy donor monocytes to FN after exposure
to dilutions of serum samples of type 1 diabetic patients (tests were
performed with 11 sera). The adhesion is expressed as a value relative
to values of healthy control sera (n  10, percentage above these
controls). B: Increased adhesion of monocytes to FN by the serum
samples of type 1 diabetic patients (f, means  SD, n  3) and the
effect of serum depletion of MRP-8/14 by monoclonal antibodies (,
means  SD, n  3). The experiment was carried out three times,
always showing the same phenomenon by MRP-8/14 depletion. Statis-
tics were performed using Mann-Whitney test.
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integrins is present that can change into a high-affinity
conformation upon activation, thus mediating adhesion
without changing the overall surface expression (45).
Determining the surface expression of the activated forms
of VLA-4 and VLA-5 using specific antibodies for such
activated forms could provide support this idea and should
be pursued.
An increased adhesion of type 1 diabetic monocytes to
FN has been previously reported, but was restricted to
monocytes of patients with poorly regulated type 1 diabe-
tes and severe vascular complications (46). None of our
patients had poorly regulated diabetes or had obvious
signs of vascular complications. Moreover, monocytes of
type 2 diabetic patients (with similar HbA1c levels and a
similar tendency to vascular complications) did not dis-
play an increased adhesion to FN.
It is interesting that the serum MRP-8/14 of type 1
diabetic patients was able to not only increase the adhe-
sion of healthy donor monocytes to FN, but also increase
the expression level of CD11b on these monocytes. In
accordance with such induction, we were able to detect an
increase in CD11b expression on monocytes of type 1
diabetic patients. However, we also found the CD18 ex-
pression on such monocytes raised, whereas MRP-8/14 in
sera of type 1 diabetic patients was not able to enhance the
expression of this integrin. Moreover, on monocytes of
type 2 diabetic patients, the CD11b and CD18 surface
expression was increased (and in this study in the absence
of increased serum MRP-8/14 levels). This showed that the
increased CD11b and CD18 surface expression on mono-
cytes of type 1 and type 2 diabetic patients cannot be due
solely to MRPs and must at least be partially explained by
consequences of the disease itself, most likely poor glyce-
mic control.
An increased expression of Mac-1 (CD11b and CD18) on
monocytes of type 1 diabetic patients has been previously
reported (46). There has also been, however, a reported
decreased expression of CD18 on isolated monocytes in
type 1 diabetic patients (47). In this latter study, mono-
cytes were tested in isolation by density gradient centrif-
ugation. We tested monocytes in “whole blood” samples
after lysis of the erythrocytes, thus reducing stimulation of
cells by the isolation procedure to a minimum. Monocytes
release Mac-1 from preexisting vesicles after stimulation,
which results in a rapid increase in surface expression
(48). Therefore, isolation procedures may influence ex-
pression levels of Mac-1 on monocytes.
If the level of MRP-8/14 is indicative of the activity of the
islet inflammatory response, it is of note that the type 1
diabetic patients used in this study had long-standing
diabetes (10 years). In most of these patients, the
pancreatic inflammation must have subsided by the time
of our study. Could it be that intrinsic (inborn) abnormal-
ities in the monocytes of type 1 diabetic patients or in their
endothelial cells force the cells to an intrinsic high pro-
duction of MRPs and other proinflammatory substances?
Such “intrinsic” abnormal “proinflammatory” monocytes
have indeed been detected in prediabetes (49) and in
FIG. 5. A and B: Flow cytometric analysis of the effect of MRP-8/14 in the serum of a type 1 diabetic patient on the surface expression of CD11b
and CD118. The experiment was performed four times, always showing the same results by MRP-8/14. C and D: CD11b surface expression on
monocytes of type 1 diabetic patients and healthy control subjects in correlation (Spearman’s rho) to the serum level of MRP-8/14 and -14.
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animal models of type 1 diabetes before islet infiltration
(6–9). The determination of MRP production by mono-
cytes of islet antibodypositive nondiabetic individuals
and patients with established prediabetes needs to be
done to answer this question (as would the simple deter-
mination of MRP-8/14 in the sera of such individuals).
In conclusion, our results showed raised levels of MRP-
8/14 and -14 in the sera of type 1 diabetic patients. These
factors are responsible for an increased adhesion of cir-
culating monocytes of type 1 diabetic patients to FN and
are at least partially responsible for an increased expres-
sion of CD11b on such monocytes. Such MRP-induced
increased adhesion most likely contributes to a facilitated
accumulation of monocytes and monocyte-derived cells at
the site of inflammation, in this case, the pancreatic islets.
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